| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 30 | 2022 | 775 | 3.580 |
Why?
|
| Viral Load | 14 | 2016 | 127 | 1.850 |
Why?
|
| Bacteremia | 13 | 2019 | 155 | 1.560 |
Why?
|
| Anti-HIV Agents | 8 | 2014 | 135 | 1.360 |
Why?
|
| Anti-Bacterial Agents | 14 | 2019 | 1026 | 1.200 |
Why?
|
| Anti-Retroviral Agents | 5 | 2019 | 53 | 0.900 |
Why?
|
| Gram-Negative Bacterial Infections | 7 | 2018 | 62 | 0.860 |
Why?
|
| HIV Integrase Inhibitors | 3 | 2013 | 12 | 0.830 |
Why?
|
| HIV-1 | 9 | 2022 | 177 | 0.780 |
Why?
|
| CD4 Lymphocyte Count | 13 | 2018 | 98 | 0.780 |
Why?
|
| Pyrrolidinones | 3 | 2013 | 15 | 0.750 |
Why?
|
| Residence Characteristics | 4 | 2016 | 252 | 0.660 |
Why?
|
| HIV | 1 | 2016 | 53 | 0.560 |
Why?
|
| Pregnancy in Adolescence | 1 | 2015 | 33 | 0.530 |
Why?
|
| Urban Health | 2 | 2015 | 49 | 0.530 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2015 | 121 | 0.530 |
Why?
|
| Rural Health | 1 | 2015 | 66 | 0.510 |
Why?
|
| South Carolina | 19 | 2018 | 2750 | 0.500 |
Why?
|
| Health Status Disparities | 2 | 2015 | 326 | 0.500 |
Why?
|
| Sexual Behavior | 1 | 2015 | 179 | 0.480 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2013 | 14 | 0.470 |
Why?
|
| Biological Therapy | 1 | 2013 | 8 | 0.460 |
Why?
|
| Transplantation | 1 | 2013 | 23 | 0.460 |
Why?
|
| Humans | 57 | 2022 | 68525 | 0.460 |
Why?
|
| Guaifenesin | 1 | 2012 | 1 | 0.460 |
Why?
|
| Feces | 1 | 2013 | 88 | 0.450 |
Why?
|
| Intestines | 1 | 2013 | 114 | 0.440 |
Why?
|
| Delayed-Action Preparations | 1 | 2012 | 120 | 0.440 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2019 | 98 | 0.430 |
Why?
|
| Disease Progression | 3 | 2015 | 1037 | 0.430 |
Why?
|
| Nanopores | 2 | 2022 | 4 | 0.430 |
Why?
|
| Microbiota | 1 | 2013 | 79 | 0.430 |
Why?
|
| Fluoroquinolones | 3 | 2016 | 49 | 0.420 |
Why?
|
| Respiratory Tract Infections | 1 | 2012 | 91 | 0.420 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2011 | 12 | 0.410 |
Why?
|
| Disabled Persons | 1 | 2012 | 94 | 0.410 |
Why?
|
| Legionella pneumophila | 1 | 2011 | 6 | 0.410 |
Why?
|
| Health Services Needs and Demand | 1 | 2012 | 149 | 0.410 |
Why?
|
| Legionnaires' Disease | 1 | 2011 | 11 | 0.410 |
Why?
|
| Hepatitis C | 3 | 2013 | 114 | 0.410 |
Why?
|
| Middle Aged | 30 | 2022 | 21119 | 0.400 |
Why?
|
| Rifampin | 1 | 2011 | 45 | 0.390 |
Why?
|
| CCR5 Receptor Antagonists | 1 | 2010 | 2 | 0.380 |
Why?
|
| Enterobacteriaceae | 4 | 2018 | 29 | 0.370 |
Why?
|
| HIV Protease Inhibitors | 1 | 2009 | 25 | 0.360 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2009 | 28 | 0.360 |
Why?
|
| Female | 35 | 2022 | 38015 | 0.350 |
Why?
|
| Male | 35 | 2022 | 37281 | 0.350 |
Why?
|
| Drug Therapy, Combination | 4 | 2019 | 648 | 0.340 |
Why?
|
| Enterobacteriaceae Infections | 3 | 2016 | 25 | 0.330 |
Why?
|
| Escherichia coli Infections | 2 | 2019 | 47 | 0.320 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2009 | 92 | 0.320 |
Why?
|
| Population Surveillance | 3 | 2016 | 285 | 0.310 |
Why?
|
| Pneumonia, Viral | 2 | 2021 | 154 | 0.310 |
Why?
|
| Health Services Accessibility | 1 | 2012 | 581 | 0.310 |
Why?
|
| Staphylococcal Infections | 1 | 2009 | 156 | 0.310 |
Why?
|
| Antiretroviral Therapy, Highly Active | 5 | 2019 | 73 | 0.300 |
Why?
|
| beta-Lactams | 2 | 2016 | 29 | 0.290 |
Why?
|
| Anti-Infective Agents | 2 | 2018 | 166 | 0.280 |
Why?
|
| Adult | 23 | 2019 | 21375 | 0.270 |
Why?
|
| Catheter-Related Infections | 2 | 2016 | 43 | 0.270 |
Why?
|
| Continuity of Patient Care | 2 | 2017 | 170 | 0.260 |
Why?
|
| Aged | 17 | 2019 | 14842 | 0.260 |
Why?
|
| Community-Acquired Infections | 2 | 2019 | 46 | 0.250 |
Why?
|
| Aged, 80 and over | 8 | 2018 | 4843 | 0.240 |
Why?
|
| Case-Control Studies | 6 | 2016 | 1548 | 0.220 |
Why?
|
| Drug Administration Schedule | 4 | 2016 | 567 | 0.210 |
Why?
|
| Raltegravir Potassium | 3 | 2013 | 6 | 0.210 |
Why?
|
| Lectins, C-Type | 1 | 2021 | 39 | 0.200 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 20 | 0.200 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 124 | 0.200 |
Why?
|
| Cardiovascular Diseases | 2 | 2022 | 938 | 0.200 |
Why?
|
| Young Adult | 9 | 2016 | 5708 | 0.200 |
Why?
|
| Adolescent | 10 | 2018 | 8903 | 0.200 |
Why?
|
| Biosensing Techniques | 1 | 2021 | 51 | 0.190 |
Why?
|
| Cell Adhesion Molecules | 1 | 2021 | 199 | 0.190 |
Why?
|
| Coronavirus | 1 | 2020 | 16 | 0.190 |
Why?
|
| Receptors, Cell Surface | 1 | 2021 | 248 | 0.190 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 110 | 0.190 |
Why?
|
| Logistic Models | 5 | 2016 | 1419 | 0.180 |
Why?
|
| Retrospective Studies | 13 | 2019 | 7264 | 0.180 |
Why?
|
| beta-Lactamases | 2 | 2016 | 33 | 0.180 |
Why?
|
| Escherichia coli | 2 | 2019 | 368 | 0.180 |
Why?
|
| Dendritic Cells | 1 | 2021 | 201 | 0.180 |
Why?
|
| Disease Notification | 3 | 2015 | 7 | 0.180 |
Why?
|
| Gram-Negative Bacteria | 2 | 2018 | 55 | 0.180 |
Why?
|
| Double-Blind Method | 3 | 2013 | 1737 | 0.170 |
Why?
|
| Program Evaluation | 2 | 2012 | 502 | 0.170 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2019 | 11 | 0.160 |
Why?
|
| Delayed Diagnosis | 1 | 2018 | 39 | 0.160 |
Why?
|
| Macrophages | 1 | 2021 | 647 | 0.160 |
Why?
|
| Pyelonephritis | 1 | 2017 | 17 | 0.150 |
Why?
|
| Levofloxacin | 1 | 2017 | 23 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 143 | 0.150 |
Why?
|
| Treatment Outcome | 8 | 2019 | 7028 | 0.150 |
Why?
|
| Vascular Access Devices | 1 | 2016 | 21 | 0.150 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2016 | 22 | 0.150 |
Why?
|
| Heterosexuality | 1 | 2016 | 16 | 0.140 |
Why?
|
| Urinary Tract Infections | 1 | 2017 | 71 | 0.140 |
Why?
|
| Acute Disease | 2 | 2021 | 658 | 0.140 |
Why?
|
| Pandemics | 1 | 2020 | 346 | 0.140 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2016 | 37 | 0.140 |
Why?
|
| Sepsis | 2 | 2017 | 233 | 0.140 |
Why?
|
| Pseudomonas Infections | 1 | 2016 | 83 | 0.140 |
Why?
|
| Sexual and Gender Minorities | 1 | 2016 | 37 | 0.140 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2016 | 133 | 0.130 |
Why?
|
| Inflammation | 1 | 2022 | 1030 | 0.130 |
Why?
|
| Drug Combinations | 3 | 2013 | 304 | 0.130 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 1293 | 0.130 |
Why?
|
| Renal Dialysis | 1 | 2016 | 174 | 0.130 |
Why?
|
| Fungemia | 1 | 2014 | 13 | 0.130 |
Why?
|
| Yeasts | 1 | 2014 | 15 | 0.130 |
Why?
|
| Socioeconomic Factors | 2 | 2015 | 955 | 0.130 |
Why?
|
| Odds Ratio | 3 | 2012 | 880 | 0.130 |
Why?
|
| Central Venous Catheters | 1 | 2014 | 19 | 0.130 |
Why?
|
| Confidence Intervals | 2 | 2012 | 242 | 0.130 |
Why?
|
| Inappropriate Prescribing | 1 | 2014 | 27 | 0.130 |
Why?
|
| Bacterial Proteins | 1 | 2016 | 244 | 0.120 |
Why?
|
| Time Factors | 5 | 2017 | 4655 | 0.120 |
Why?
|
| Mycoses | 1 | 2014 | 60 | 0.120 |
Why?
|
| Prevalence | 3 | 2015 | 1609 | 0.120 |
Why?
|
| Antifungal Agents | 1 | 2014 | 108 | 0.120 |
Why?
|
| Catheterization, Central Venous | 1 | 2014 | 89 | 0.120 |
Why?
|
| Drug Resistance, Viral | 2 | 2011 | 14 | 0.120 |
Why?
|
| Cerebrovascular Disorders | 1 | 2014 | 182 | 0.120 |
Why?
|
| Patient Isolation | 1 | 2013 | 35 | 0.120 |
Why?
|
| Expectorants | 1 | 2012 | 5 | 0.110 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 365 | 0.110 |
Why?
|
| Length of Stay | 1 | 2016 | 780 | 0.110 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2013 | 226 | 0.110 |
Why?
|
| Hepatitis | 1 | 2012 | 25 | 0.110 |
Why?
|
| Anemia, Sickle Cell | 1 | 2016 | 364 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 378 | 0.110 |
Why?
|
| Nitriles | 1 | 2012 | 68 | 0.110 |
Why?
|
| Drug Hypersensitivity | 1 | 2012 | 35 | 0.110 |
Why?
|
| Dyslipidemias | 1 | 2013 | 98 | 0.110 |
Why?
|
| Statistics as Topic | 1 | 2012 | 219 | 0.110 |
Why?
|
| Risk Factors | 7 | 2017 | 5719 | 0.100 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 1851 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2012 | 178 | 0.100 |
Why?
|
| Program Development | 1 | 2012 | 240 | 0.100 |
Why?
|
| Coinfection | 1 | 2011 | 29 | 0.100 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2011 | 47 | 0.100 |
Why?
|
| Pregnancy | 2 | 2015 | 2331 | 0.100 |
Why?
|
| Multivariate Analysis | 4 | 2016 | 1046 | 0.100 |
Why?
|
| Drug Interactions | 1 | 2011 | 289 | 0.100 |
Why?
|
| Adenylate Kinase | 1 | 2010 | 10 | 0.100 |
Why?
|
| Bryostatins | 1 | 2010 | 32 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2022 | 507 | 0.090 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2009 | 1 | 0.090 |
Why?
|
| Wounds, Stab | 1 | 2009 | 7 | 0.090 |
Why?
|
| Prisons | 1 | 2009 | 18 | 0.090 |
Why?
|
| Placebos | 1 | 2010 | 195 | 0.090 |
Why?
|
| National Health Programs | 1 | 2009 | 11 | 0.090 |
Why?
|
| AIDS Serodiagnosis | 1 | 2009 | 17 | 0.090 |
Why?
|
| Registries | 1 | 2012 | 730 | 0.090 |
Why?
|
| Protein Kinase C | 1 | 2010 | 270 | 0.090 |
Why?
|
| Prognosis | 4 | 2017 | 2093 | 0.080 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2008 | 4 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2012 | 1341 | 0.080 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2008 | 32 | 0.080 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2008 | 29 | 0.080 |
Why?
|
| Proportional Hazards Models | 3 | 2014 | 791 | 0.080 |
Why?
|
| Risk | 1 | 2009 | 563 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2022 | 1753 | 0.080 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2008 | 126 | 0.080 |
Why?
|
| United States | 3 | 2017 | 7335 | 0.070 |
Why?
|
| Tenofovir | 2 | 2019 | 10 | 0.070 |
Why?
|
| Oxazines | 2 | 2019 | 10 | 0.070 |
Why?
|
| Adenine | 2 | 2019 | 46 | 0.070 |
Why?
|
| Pyridones | 2 | 2019 | 40 | 0.070 |
Why?
|
| Lung | 2 | 2021 | 849 | 0.070 |
Why?
|
| Treatment Failure | 2 | 2017 | 216 | 0.070 |
Why?
|
| Crime Victims | 1 | 2009 | 286 | 0.070 |
Why?
|
| Risk Assessment | 3 | 2016 | 2004 | 0.070 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2005 | 9 | 0.070 |
Why?
|
| Piperazines | 2 | 2019 | 206 | 0.070 |
Why?
|
| Malaria | 1 | 2005 | 26 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2017 | 2356 | 0.060 |
Why?
|
| Hospitals | 2 | 2016 | 265 | 0.060 |
Why?
|
| RNA, Viral | 2 | 2015 | 93 | 0.060 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2017 | 226 | 0.060 |
Why?
|
| Rural Population | 2 | 2017 | 397 | 0.060 |
Why?
|
| Infant | 2 | 2007 | 2891 | 0.060 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2005 | 199 | 0.060 |
Why?
|
| HIV Core Protein p24 | 1 | 2022 | 5 | 0.060 |
Why?
|
| Click Chemistry | 1 | 2022 | 7 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2014 | 536 | 0.060 |
Why?
|
| Cell Cycle | 1 | 2004 | 312 | 0.050 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2022 | 18 | 0.050 |
Why?
|
| Lamivudine | 2 | 2013 | 24 | 0.050 |
Why?
|
| Nasopharynx | 1 | 2021 | 7 | 0.050 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2021 | 10 | 0.050 |
Why?
|
| B7-1 Antigen | 1 | 2021 | 20 | 0.050 |
Why?
|
| Lentivirus | 1 | 2021 | 35 | 0.050 |
Why?
|
| RAW 264.7 Cells | 1 | 2021 | 42 | 0.050 |
Why?
|
| Datasets as Topic | 1 | 2021 | 52 | 0.050 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 35 | 0.050 |
Why?
|
| Viral Envelope Proteins | 1 | 2021 | 43 | 0.050 |
Why?
|
| Sex Factors | 2 | 2016 | 1265 | 0.050 |
Why?
|
| Histones | 1 | 2022 | 111 | 0.050 |
Why?
|
| Alveolar Epithelial Cells | 1 | 2021 | 28 | 0.050 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 69 | 0.050 |
Why?
|
| PPAR gamma | 1 | 2021 | 95 | 0.050 |
Why?
|
| Incidence | 2 | 2015 | 1582 | 0.050 |
Why?
|
| Interleukin-10 | 1 | 2021 | 144 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2010 | 2688 | 0.050 |
Why?
|
| Immunity, Innate | 1 | 2021 | 156 | 0.050 |
Why?
|
| DNA Methylation | 1 | 2022 | 192 | 0.050 |
Why?
|
| Transcriptome | 1 | 2022 | 164 | 0.050 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 163 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2005 | 1173 | 0.050 |
Why?
|
| Immunoglobulin M | 1 | 2021 | 172 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2021 | 240 | 0.050 |
Why?
|
| China | 1 | 2020 | 138 | 0.050 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 244 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2021 | 330 | 0.050 |
Why?
|
| Emtricitabine | 1 | 2019 | 5 | 0.040 |
Why?
|
| Serogroup | 1 | 2019 | 6 | 0.040 |
Why?
|
| Gene Expression | 1 | 2022 | 770 | 0.040 |
Why?
|
| Alanine | 1 | 2019 | 38 | 0.040 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2019 | 34 | 0.040 |
Why?
|
| Early Diagnosis | 2 | 2009 | 122 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2021 | 370 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 116 | 0.040 |
Why?
|
| Cholesterol | 1 | 2020 | 331 | 0.040 |
Why?
|
| Amides | 1 | 2019 | 86 | 0.040 |
Why?
|
| Seasons | 1 | 2019 | 129 | 0.040 |
Why?
|
| Healthcare Financing | 1 | 2018 | 3 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 481 | 0.040 |
Why?
|
| DNA | 1 | 2021 | 597 | 0.040 |
Why?
|
| Propensity Score | 1 | 2018 | 116 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2018 | 105 | 0.040 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2017 | 19 | 0.040 |
Why?
|
| Cell Line | 1 | 2021 | 1752 | 0.040 |
Why?
|
| Biological Availability | 1 | 2016 | 79 | 0.040 |
Why?
|
| Canada | 1 | 2017 | 266 | 0.040 |
Why?
|
| Hospitals, Community | 1 | 2016 | 64 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 503 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 714 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 238 | 0.030 |
Why?
|
| Southeastern United States | 1 | 2016 | 281 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 411 | 0.030 |
Why?
|
| Urban Population | 1 | 2016 | 254 | 0.030 |
Why?
|
| Voriconazole | 1 | 2014 | 11 | 0.030 |
Why?
|
| Amphotericin B | 1 | 2014 | 26 | 0.030 |
Why?
|
| Fluconazole | 1 | 2014 | 26 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 2790 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2015 | 272 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 319 | 0.030 |
Why?
|
| Dideoxynucleosides | 1 | 2013 | 1 | 0.030 |
Why?
|
| Organophosphonates | 1 | 2013 | 16 | 0.030 |
Why?
|
| Epidemiological Monitoring | 1 | 2013 | 23 | 0.030 |
Why?
|
| Rilpivirine | 1 | 2012 | 1 | 0.030 |
Why?
|
| Liver Function Tests | 1 | 2012 | 114 | 0.030 |
Why?
|
| Medicaid | 1 | 2014 | 301 | 0.030 |
Why?
|
| Drug Resistance, Multiple, Viral | 1 | 2011 | 4 | 0.030 |
Why?
|
| Virus Latency | 1 | 2010 | 10 | 0.020 |
Why?
|
| Comorbidity | 1 | 2014 | 1425 | 0.020 |
Why?
|
| Lopinavir | 1 | 2009 | 18 | 0.020 |
Why?
|
| Zidovudine | 1 | 2009 | 27 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 693 | 0.020 |
Why?
|
| Disease Transmission, Infectious | 1 | 2009 | 25 | 0.020 |
Why?
|
| Pyrimidinones | 1 | 2009 | 26 | 0.020 |
Why?
|
| Hepatitis B | 1 | 2009 | 42 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2007 | 2264 | 0.020 |
Why?
|
| Prisoners | 1 | 2009 | 50 | 0.020 |
Why?
|
| Mice | 1 | 2021 | 8472 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2009 | 91 | 0.020 |
Why?
|
| Animals | 2 | 2021 | 20877 | 0.020 |
Why?
|
| Cercocebus atys | 1 | 2008 | 2 | 0.020 |
Why?
|
| Simian Immunodeficiency Virus | 1 | 2008 | 28 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2010 | 331 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 3256 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2009 | 621 | 0.020 |
Why?
|
| Gene Products, gag | 1 | 2005 | 11 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2005 | 31 | 0.020 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2005 | 38 | 0.020 |
Why?
|
| Salmonella Infections | 1 | 2005 | 11 | 0.020 |
Why?
|
| Pregnancy Complications, Parasitic | 1 | 2005 | 6 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2005 | 110 | 0.020 |
Why?
|
| Emigration and Immigration | 1 | 2005 | 33 | 0.020 |
Why?
|
| Travel | 1 | 2005 | 38 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2010 | 2673 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 2005 | 75 | 0.020 |
Why?
|
| Georgia | 1 | 2005 | 161 | 0.020 |
Why?
|
| Antimalarials | 1 | 2005 | 71 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2005 | 133 | 0.020 |
Why?
|
| Nucleolus Organizer Region | 1 | 2004 | 2 | 0.020 |
Why?
|
| Cyclin B | 1 | 2004 | 4 | 0.020 |
Why?
|
| Cyclin B1 | 1 | 2004 | 7 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2005 | 100 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2004 | 37 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2005 | 179 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2005 | 241 | 0.010 |
Why?
|
| Retinoblastoma Protein | 1 | 2004 | 75 | 0.010 |
Why?
|
| Algorithms | 1 | 2009 | 1194 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2005 | 397 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2005 | 265 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2004 | 1054 | 0.010 |
Why?
|
| Biomarkers | 1 | 2005 | 1593 | 0.010 |
Why?
|
| Apoptosis | 1 | 2005 | 1640 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2005 | 3185 | 0.010 |
Why?
|
| Child | 1 | 2005 | 6400 | 0.010 |
Why?
|